2 1 Shi Ji Jing Ji Bao Dao·2025-07-11 04:20Group 1 - The CRO (Contract Research Organization) sector is experiencing a surge in stock prices, with notable increases in companies such as Boteng Co., Ltd. (20% increase), Kailaiying (10% increase), and WuXi AppTec (9.99% increase) [1][2][3] - The Hong Kong CXO concept stocks also saw significant gains, with Kailaiying and WuXi AppTec both rising over 10% [3][4] - WuXi AppTec is projected to achieve approximately RMB 20.8 billion in revenue for the first half of 2025, representing a year-on-year growth of about 20.64%, and an adjusted net profit of approximately RMB 6.315 billion, reflecting a year-on-year increase of about 44.43% [4][5] Group 2 - The growth in performance for WuXi AppTec is attributed to its focus on meeting customer demands, expanding capabilities, and optimizing production processes [5] - The CXO sector is expected to benefit significantly from the current high demand for innovative drugs, with a new upturn in the life sciences and CXO sectors anticipated [5][6] - Analysts predict that the CXO sector will see a recovery in domestic front-end business due to supportive industrial policies and improved investment conditions [6] Group 3 - The current wave of innovation in the pharmaceutical sector is seen as a significant turning point, with a shift from following trends to creating original products, indicating a fundamental change in the industry [7][8] - Large multinational pharmaceutical companies are increasingly purchasing innovative drug patents from China, driven by pressures to lower drug prices and the expiration of patents [8]